NO20091251L - Nikotinisk acetylkolinreseptorsubtype selektive amider av diazabicykloalkaner - Google Patents

Nikotinisk acetylkolinreseptorsubtype selektive amider av diazabicykloalkaner

Info

Publication number
NO20091251L
NO20091251L NO20091251A NO20091251A NO20091251L NO 20091251 L NO20091251 L NO 20091251L NO 20091251 A NO20091251 A NO 20091251A NO 20091251 A NO20091251 A NO 20091251A NO 20091251 L NO20091251 L NO 20091251L
Authority
NO
Norway
Prior art keywords
compounds
effects
diazabicycloalkanes
significant
sns
Prior art date
Application number
NO20091251A
Other languages
English (en)
Norwegian (no)
Inventor
Craig H Miller
Anatoly A Mazurov
Lan Miao
Yun-De Xiao
Philip S Hammond
Srinivisa Rao Akireddy
V Srinivisa Murthy
Regina C Whitaker
Scott R Breining
Matt S Melvin
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of NO20091251L publication Critical patent/NO20091251L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20091251A 2006-11-02 2009-03-26 Nikotinisk acetylkolinreseptorsubtype selektive amider av diazabicykloalkaner NO20091251L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85607906P 2006-11-02 2006-11-02
PCT/US2007/083330 WO2008057938A1 (en) 2006-11-02 2007-11-01 Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes

Publications (1)

Publication Number Publication Date
NO20091251L true NO20091251L (no) 2009-05-28

Family

ID=39233054

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091251A NO20091251L (no) 2006-11-02 2009-03-26 Nikotinisk acetylkolinreseptorsubtype selektive amider av diazabicykloalkaner

Country Status (32)

Country Link
US (6) US8114889B2 (https=)
EP (2) EP2284171B1 (https=)
JP (2) JP5539723B2 (https=)
KR (2) KR101415705B1 (https=)
CN (4) CN102838605B (https=)
AR (2) AR063451A1 (https=)
AT (2) ATE509022T1 (https=)
AU (2) AU2007317433B2 (https=)
BR (2) BRPI0717930A2 (https=)
CA (1) CA2663925C (https=)
CL (1) CL2007003155A1 (https=)
CO (1) CO6180435A2 (https=)
CY (1) CY1112374T1 (https=)
DK (1) DK2094703T3 (https=)
ES (2) ES2395212T3 (https=)
HR (1) HRP20110570T1 (https=)
IL (2) IL197618A (https=)
MX (1) MX2009004801A (https=)
MY (2) MY156730A (https=)
NO (1) NO20091251L (https=)
NZ (2) NZ587847A (https=)
PE (2) PE20110671A1 (https=)
PL (1) PL2094703T3 (https=)
PT (1) PT2094703E (https=)
RS (1) RS51834B (https=)
RU (2) RU2448969C2 (https=)
SA (1) SA07280584B1 (https=)
SI (1) SI2094703T1 (https=)
TW (3) TWI405763B (https=)
UA (2) UA98944C2 (https=)
UY (1) UY30686A1 (https=)
WO (1) WO2008057938A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI405763B (zh) * 2006-11-02 2013-08-21 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
JP2011513421A (ja) * 2008-03-05 2011-04-28 ターガセプト,インコーポレイテッド サブタイプ選択的なジアザビシクロアルカンのアミド
WO2009113950A1 (en) * 2008-03-10 2009-09-17 Astrazeneca Ab Therapeutic combinations of (a) an antipsychotic and (b) an alpha-4/beta-2 (a4b2)-neuronal nicotinic receptor agonist
ES2383246T3 (es) 2008-06-05 2012-06-19 Glaxo Group Limited 4-amino-indazoles
US8658635B2 (en) 2008-06-05 2014-02-25 Glaxosmithkline Intellectual Property Development Limited Benzpyrazol derivatives as inhibitors of PI3 kinases
JP5502076B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規化合物
WO2010028011A1 (en) * 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
WO2010028033A1 (en) * 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclooctanes and uses thereof
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドGlaxo Group Limited Pi3キナーゼの阻害剤としての4−オキサジアゾール−2−イル−インダゾール
WO2010125082A1 (en) 2009-04-30 2010-11-04 Glaxo Group Limited Oxazole substituted indazoles as pi3-kinase inhibitors
RU2417082C2 (ru) * 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
DK2513085T3 (en) 2009-11-18 2016-12-05 Suven Life Sciences Ltd Alfa4beta2 bicyclic compounds as nicotinic acetylcholine receptor ligands
BR112012016201A2 (pt) 2009-12-29 2017-12-19 Suven Life Sciences Ltd ''composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto''
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
CN105764905B (zh) 2013-11-26 2019-06-07 豪夫迈·罗氏有限公司 新的八氢-环丁二烯并[1,2-c;3,4-c’]二吡咯-2基
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
SG10202011669PA (en) 2014-10-20 2020-12-30 Oyster Point Pharma Inc Methods of treating ocular conditions
CA2992889A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
RU2018112230A (ru) 2015-09-24 2019-10-30 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов atx
KR20180054830A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 오토탁신(atx) 억제제로서의 이환형 화합물
AU2016328365B2 (en) * 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
CR20180057A (es) * 2015-09-24 2018-04-02 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
CN109310692B (zh) 2016-04-07 2022-01-25 奥伊斯特普安生物制药公司 治疗眼部病状的方法
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
SG11201908560SA (en) 2017-03-16 2019-10-30 Hoffmann La Roche Heterocyclic compounds useful as dual atx/ca inhibitors
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
US20220378756A1 (en) 2019-09-19 2022-12-01 Forma Therapeutics, Inc. Activating pyruvate kinase r
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5468858A (en) 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
CZ282567B6 (cs) * 1993-12-29 1997-08-13 Pfizer Inc. Diazabicyklické sloučeniny a farmaceutické prostředky na jejich bázi
US5457121A (en) 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
MXPA02005884A (es) * 1999-12-14 2002-10-23 Neurosearch As Heteroaril-diazabicicloalcanos novedosos.
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
CA2440803A1 (en) 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
MXPA04000012A (es) 2001-07-06 2004-05-21 Neurosearch As Compuestos novedosos, su preparacion y uso.
SE0202465D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
SE0202430D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
MXPA05006861A (es) * 2003-02-27 2005-12-12 Neurosearch As Derivados arildiazabiciclicos novedosos.
CN1317280C (zh) * 2003-02-27 2007-05-23 神经研究公司 新的二氮杂双环芳基衍生物
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US7365193B2 (en) * 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
RU2006146608A (ru) * 2004-06-09 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) ОКТАГИДРОПИРРОЛО[3,4-с]-ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ АГЕНТОВ
EP1781670A1 (en) 2004-07-22 2007-05-09 Cumbre Pharmaceuticals Inc. Rifamycin derivatives for treating microbial infections
US20060258672A1 (en) * 2005-05-13 2006-11-16 Joseph Barbosa Multicyclic compounds and methods of their use
TWI405763B (zh) * 2006-11-02 2013-08-21 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺

Also Published As

Publication number Publication date
BRPI0717930A2 (pt) 2011-05-10
ES2395212T3 (es) 2013-02-11
IL209026A (en) 2014-03-31
US8859609B2 (en) 2014-10-14
CO6180435A2 (es) 2010-07-19
CA2663925C (en) 2015-04-21
US9580434B2 (en) 2017-02-28
US20120289572A1 (en) 2012-11-15
MY145602A (en) 2012-03-15
ATE509022T1 (de) 2011-05-15
CN102020646A (zh) 2011-04-20
RU2517693C2 (ru) 2014-05-27
US8114889B2 (en) 2012-02-14
IL197618A (en) 2013-09-30
PL2094703T3 (pl) 2011-10-31
NZ587847A (en) 2011-09-30
RU2009120674A (ru) 2010-12-10
PT2094703E (pt) 2011-07-22
BRPI0722387A2 (pt) 2023-02-23
PE20110671A1 (es) 2011-10-20
CN102838605B (zh) 2017-04-26
US20130005789A1 (en) 2013-01-03
AU2010219323B2 (en) 2012-05-03
CN101528745A (zh) 2009-09-09
AU2007317433A1 (en) 2008-05-15
DK2094703T3 (da) 2011-08-29
ES2395157T3 (es) 2013-02-08
KR20100124356A (ko) 2010-11-26
RU2009138600A (ru) 2011-04-27
AU2007317433B2 (en) 2012-05-10
HK1133260A1 (en) 2010-03-19
AR063451A1 (es) 2009-01-28
CN102020646B (zh) 2013-11-13
KR20090074051A (ko) 2009-07-03
AU2010219323A1 (en) 2010-09-30
TWI405763B (zh) 2013-08-21
HK1149751A1 (en) 2011-10-14
WO2008057938A1 (en) 2008-05-15
CL2007003155A1 (es) 2008-05-16
PE20081441A1 (es) 2008-10-30
TW201305176A (zh) 2013-02-01
IL209026A0 (en) 2011-01-31
JP2010509230A (ja) 2010-03-25
MY156730A (en) 2016-03-15
AR079840A2 (es) 2012-02-22
ATE545646T1 (de) 2012-03-15
US8921410B2 (en) 2014-12-30
HRP20110570T1 (hr) 2011-09-30
CN102942569B (zh) 2015-10-28
JP5739398B2 (ja) 2015-06-24
JP5539723B2 (ja) 2014-07-02
EP2284171A1 (en) 2011-02-16
EP2094703A1 (en) 2009-09-02
MX2009004801A (es) 2009-07-31
CA2663925A1 (en) 2008-05-15
TWI454262B (zh) 2014-10-01
EP2094703B1 (en) 2011-05-11
CY1112374T1 (el) 2015-12-09
US20100173932A1 (en) 2010-07-08
RU2448969C2 (ru) 2012-04-27
UA106718C2 (uk) 2014-10-10
EP2284171B1 (en) 2012-02-15
TW201114424A (en) 2011-05-01
UA98944C2 (ru) 2012-07-10
US20100081683A1 (en) 2010-04-01
SI2094703T1 (sl) 2011-07-29
US20150080576A1 (en) 2015-03-19
TWI404532B (zh) 2013-08-11
TW200826935A (en) 2008-07-01
RS51834B (sr) 2012-02-29
NZ575557A (en) 2011-01-28
US20160039833A1 (en) 2016-02-11
US8268860B2 (en) 2012-09-18
UY30686A1 (es) 2009-08-03
CN101528745B (zh) 2011-09-14
CN102942569A (zh) 2013-02-27
IL197618A0 (en) 2009-12-24
SA07280584B1 (ar) 2010-11-02
CN102838605A (zh) 2012-12-26
JP2013056919A (ja) 2013-03-28
KR101415705B1 (ko) 2014-07-04

Similar Documents

Publication Publication Date Title
NO20091251L (no) Nikotinisk acetylkolinreseptorsubtype selektive amider av diazabicykloalkaner
WO2004005293A3 (en) N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2007125501A3 (en) Liquid compositions comprising phenylephrine and acetaminophen and their use for the treatment of respiratory illness
MX2010004026A (es) Piperidino-dihidrotienopirimidinas sustituidas.
WO2005080343A3 (en) 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators
MX2010004494A (es) Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
WO2008050101A3 (en) Benzoyl amino heterocyclyl compounds useful in the treatment of a disease mediated through glk
WO2007062078A3 (en) Thrombopoietin activity modulating compounds and methods
MY144132A (en) Polymorph forms of (2s)-(4e)-n-methyl-5-[3-(5-isoproproxypyridin)yl]-4-penten-2-amine
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson&#39;s disease
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
EP2305640A3 (en) Substituted diphenyl-ethers, -amines, -sulfides and -methanes for the treatment of respiratory diseases
TW200630336A (en) Novel compounds
WO2011112867A8 (en) The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
TW200621690A (en) Novel compounds
MX2009010630A (es) Derivados de azabicicloalcano selectivos de sub-tipo.
WO2008020306A3 (en) Isoindole derivatives
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2006067428A3 (en) 1, 2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands
UA88634C2 (en) Quaternized quinuclidine esters
WO2007100430A3 (en) Cytisine and acetylcholine analogs and methods of treating mood disorders
UY30959A1 (es) Subtipo de amidas selectivas de diazabicicloalcanos
WO2005112923A3 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application